Efficacy News and Research

RSS
Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Vascular Insights wins CE Mark approval for ClariVein Occlusion Catheter

Vascular Insights wins CE Mark approval for ClariVein Occlusion Catheter

Elixir Medical announces presentations from EXCELLA II Clinical Trial at 2010 EuroPCR

Elixir Medical announces presentations from EXCELLA II Clinical Trial at 2010 EuroPCR

BioLife Solutions first-quarter revenue up 36% to $513,000

BioLife Solutions first-quarter revenue up 36% to $513,000

PurGenesis completes development of novel anti-aging cosmeceutical products

PurGenesis completes development of novel anti-aging cosmeceutical products

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma closes $43 million Series B financing round

Spanish researchers reprogram adult stem cells to help cardiac muscle regeneration

Spanish researchers reprogram adult stem cells to help cardiac muscle regeneration

70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommendations

70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommendations

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

eMedonline telemonitoring system developed to help patients transition from inpatient to outpatient setting

eMedonline telemonitoring system developed to help patients transition from inpatient to outpatient setting

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Flexible treatment delivery intervention in primary care reduces symptoms of anxiety: Study

Flexible treatment delivery intervention in primary care reduces symptoms of anxiety: Study

Use of life-ending drugs without explicit patient request occurs in hospital, among elderly patients

Use of life-ending drugs without explicit patient request occurs in hospital, among elderly patients

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

PET scanning provides great insight into immune response

PET scanning provides great insight into immune response

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.